Logo image of DWTX

DOGWOOD THERAPEUTICS INC (DWTX) Stock Fundamental Analysis

NASDAQ:DWTX - US92829J2033 - Common Stock

4.8101 USD
-0.15 (-3.02%)
Last: 9/2/2025, 8:00:01 PM
Fundamental Rating

3

DWTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. DWTX has a great financial health rating, but its profitability evaluates not so good. DWTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DWTX has reported negative net income.
DWTX had a negative operating cash flow in the past year.
DWTX had negative earnings in each of the past 5 years.
In the past 5 years DWTX always reported negative operating cash flow.
DWTX Yearly Net Income VS EBIT VS OCF VS FCFDWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

DWTX's Return On Assets of -27.42% is fine compared to the rest of the industry. DWTX outperforms 70.48% of its industry peers.
Looking at the Return On Equity, with a value of -32.12%, DWTX is in the better half of the industry, outperforming 76.20% of the companies in the same industry.
Industry RankSector Rank
ROA -27.42%
ROE -32.12%
ROIC N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
DWTX Yearly ROA, ROE, ROICDWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

DWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DWTX Yearly Profit, Operating, Gross MarginsDWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, DWTX has more shares outstanding
Compared to 5 years ago, DWTX has less shares outstanding
DWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DWTX Yearly Shares OutstandingDWTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
DWTX Yearly Total Debt VS Total AssetsDWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.35, we must say that DWTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DWTX (-1.35) is comparable to the rest of the industry.
There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.35
ROIC/WACCN/A
WACCN/A
DWTX Yearly LT Debt VS Equity VS FCFDWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 7.80 indicates that DWTX has no problem at all paying its short term obligations.
DWTX's Current ratio of 7.80 is fine compared to the rest of the industry. DWTX outperforms 73.25% of its industry peers.
A Quick Ratio of 7.80 indicates that DWTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.80, DWTX is in the better half of the industry, outperforming 73.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 7.8
DWTX Yearly Current Assets VS Current LiabilitesDWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

DWTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -135.00%.
EPS 1Y (TTM)-135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.65%
EPS Next 2Y25.62%
EPS Next 3Y17.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DWTX Yearly Revenue VS EstimatesDWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 20M 40M 60M 80M 100M
DWTX Yearly EPS VS EstimatesDWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DWTX Price Earnings VS Forward Price EarningsDWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DWTX Per share dataDWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

A more expensive valuation may be justified as DWTX's earnings are expected to grow with 17.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.62%
EPS Next 3Y17.55%

More info and screens

0

5. Dividend

5.1 Amount

DWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DOGWOOD THERAPEUTICS INC

NASDAQ:DWTX (9/2/2025, 8:00:01 PM)

4.8101

-0.15 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners7.29%
Inst Owner Change-33.6%
Ins Owners2.01%
Ins Owner Change0%
Market Cap9.19M
Analysts82.5
Price Target17.34 (260.49%)
Short Float %2.82%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-37.82%
Min EPS beat(2)-72.96%
Max EPS beat(2)-2.68%
EPS beat(4)0
Avg EPS beat(4)-113.29%
Min EPS beat(4)-306.71%
Max EPS beat(4)-2.68%
EPS beat(8)3
Avg EPS beat(8)-53.68%
EPS beat(12)6
Avg EPS beat(12)-25.52%
EPS beat(16)10
Avg EPS beat(16)-14.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.94%
EPS NQ rev (3m)-2370%
EPS NY rev (1m)-3.17%
EPS NY rev (3m)-10.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 11.8
EV/EBITDA N/A
EPS(TTM)-14.1
EYN/A
EPS(NY)-4.61
Fwd EYN/A
FCF(TTM)-8.25
FCFYN/A
OCF(TTM)-8.25
OCFYN/A
SpS0
BVpS43.21
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.42%
ROE -32.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.8
Quick Ratio 7.8
Altman-Z -1.35
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.2%
EPS Next Y7.65%
EPS Next 2Y25.62%
EPS Next 3Y17.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-234.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-107.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.23%
OCF growth 3YN/A
OCF growth 5YN/A